Early Access — free while we kick the tires
EdgarHawk

Kintz Samuel

PRESIDENT AND CEO

Director Officer
1 filing analyzed · 1 company · Latest 2024-10-10

Companies

Company Buys Sells Direction
Enliven Therapeutics, Inc. ELVN 0 4 Net selling

Activity

October 2024
high
Sell
29,977 shares
$841,334
Significance 6/10

CEO Samuel Kintz sold 30.0K shares of ELVN for $841.3K (blended avg $28.07) in 4 separate transactions; stock down 4.4% from 52-week high despite +15.9% 30-day gain.

Samuel Kintz, President and CEO, executed 4 separate sales totaling 29,977 shares on October 8–9, 2024, reducing his holdings from 1,033,793 to 1,003,816 shares (-2.9%). The transactions occurred at prices ranging from $27.95 to $28.53, with a blended average of $28.07. The company reported a full-year net loss of $-19,950,000.00, and the stock is currently trading at $26.97 — below the transaction price and 4.4% below its 52-week high of $28.21. Notably, Kintz's prior sell at ELVN (April 11, 2024) showed negative 90-day returns of -7.9%, aligning with his cross-ticker track record of 100.00% well-timed sells. The current sale follows a +15.9% 30-day rally, placing the stock near recent highs before the recent pullback to current levels.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access